Phaseline

Companies › New Cancer Cure-Bio

New Cancer Cure-Bio: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Sep 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
KN510–Phase 1Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)Sep 2028
KN713–Phase 1Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)Sep 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07114861KN510Phase 1Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)OncologySep 2028
NCT07114861KN713Phase 1Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)OncologySep 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.